News | April 21, 2009

Tomotherapy Shows Prostate Motion Affects Target Dose Only Slightly

April 21, 2009 – In a study in which researchers from the MD Anderson Cancer Centre Orlando, FL, and the University of Wisconsin, Madison, conducted an analysis of prostate motion during helical tomotherapy, they concluded that the impact on target dose is actually quite small (Int. J. Rad. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2008.09.035).

The study marked the first time that helical tomotherapy has been considered in similar detail. Researchers used electromagnetic markers by Calypso Medical Technologies to track prostate motion. Three markers were implanted under ultrasound guidance in 16 patients who went on to receive IMRT. Tomotherapy treatment plans were generated retrospectively and compared with motion tracks from the markers.

Two separate scenarios were considered. The first assumed that treatment started at the beginning of the observation period. The second anticipated an estimated delay of five minutes between patient alignment and the start of treatment. The minimum dose (Dmin), maximum dose (Dmax) and dose to 95 percent of the volume (D95 percent) were calculated for the whole prostate and for the planning target volume (PTV). These values were then compared with the doses that would have been delivered had the prostate stayed still. The cumulative effect was also evaluated over the course of treatment.

The results showed that for individual fractions, target D95 percent could be reduced by as much as 20 percent. However, the effect of such sizeable dose reductions diminished quickly as treatment continued. The effect on target D95 percent was less than 1 percent by the time that five fractions had been delivered. The biggest surprise was the similarity in observed changes to D95 percent for the prostate and the PTV.

While the results only apply to whole-prostate tomotherapy, researchers will test other techniques that may be affected more by organ motion, such as dose-painting, in a follow-up study.

For more information: www.redjournal.org

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more